Tag: Oncogenic Viruses

Development of diarylpyrimidine derivatives (& other heterocycles) as HIV-1 and WTRT inhibitors

Reverse transcriptase (RT) is an enzyme encoded by the genetic material of retroviruses. Viruses such as HIV and hepatitis B employ an enzyme reverse transcriptase (RT) to generate complementary DNA from the RNA template during reverse transcription. Thus, viruses replicate their genomes and proliferate within the host genome. In particular, researchers are concerned about the… Continue reading Development of diarylpyrimidine derivatives (& other heterocycles) as HIV-1 and WTRT inhibitors

TWiV 1164: Clinical update with Dr. Daniel Griffin

In his weekly clinical update, Dr. Griffin informs us about the World Health Organization research and development plan to combat endemic pathogens including hepatitis C virus, RSV and dengue virus, another case of mpox in Britian, the Marburg virus outbreak in Rwanda, before reviewing the recent statistics on SARS-CoV-2 infection, the WasterwaterScan dashboard, if there… Continue reading TWiV 1164: Clinical update with Dr. Daniel Griffin

Letter to the Editor regarding “Clinical validation of a tissue-agnostic genome-wide methylome enrichment molecular residual disease assay for head and neck malignancies” by G Liu et al

We read with great interest the article by Liu et al., titled ” Clinical validation of a tissue-agnostic genome-wide methylome enrichment molecular residual disease assay for head and neck malignancies”[1]. This study substantiates the potential utility of a tissue-independent genome-wide methylation MRD assay in patients with head and neck cancer, demonstrating high sensitivity in both… Continue reading Letter to the Editor regarding “Clinical validation of a tissue-agnostic genome-wide methylome enrichment molecular residual disease assay for head and neck malignancies” by G Liu et al

Limited stability of Hepatitis B virus RNA in plasma and serum

Abstract Pregenomic hepatitis B virus RNA (HBV pgRNA) is a potential biomarker in the management of HBV infected patients. However, prior to the use in routine clinical practice potential confounders of test results need to be identified. This study investigates the stability of HBV pgRNA under various storage conditions. HBV-RNA level of 26 HBV patients… Continue reading Limited stability of Hepatitis B virus RNA in plasma and serum

Advancing vaccine development through green biotechnology

The diseases hepatitis B (HBV) and C (HCV) remain a significant health threat worldwide, causing approximately 1.3 million deaths each year. In Romania, the prevalence of both diseases is notably high, creating an urgent need for more accessible prevention methods. The current HBV vaccine fails to protect approximately 10 % of vaccinated individuals, and the… Continue reading Advancing vaccine development through green biotechnology

1481 Off-the-shelf dark matter immunotherapy in head & neck cancer: mechanistic insights and clinical efficacy

Background DPV-001 is an off-the-shelf biologic containing proteins that are overexpressed by adenocarcinoma and squamous cell cancers. It is enriched for short-lived proteins (SLiPs) and defective ribosomal products (DRiPs), containing canonical and non-canonical alternative cancer neoantigens (dark matter, at least 30 microproteins) in spectrin-coated microvesicles targeted to CLEC9A+ conventional dendritic cells (cDC).1 2 Preclinical models… Continue reading 1481 Off-the-shelf dark matter immunotherapy in head & neck cancer: mechanistic insights and clinical efficacy

1480 Eseba-vec (HB-200) plus pembrolizumab as first-line treatment of recurrent/metastatic HPV16-positive head and neck cancer: updated results in PD-L1 CPS >=20 patients

Background Only a minority of patients (20%) with Human Papillomavirus (HPV) 16-positive recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) responds to first-line (1L) monotherapy with pembrolizumab, and no approved therapies exist targeting HPV+ disease specifically. Eseba-vec (previously known as HB-200) utilizes arenavirus vectors to induce potent HPV-16 E6 and E7-specific CD8 T-cell responses.… Continue reading 1480 Eseba-vec (HB-200) plus pembrolizumab as first-line treatment of recurrent/metastatic HPV16-positive head and neck cancer: updated results in PD-L1 CPS >=20 patients